DRRX - DURECT Corporation
| Previous Close | 0.7000 |
| Open | 0.7000 |
| Bid | 0.0000 x 4000 |
| Ask | 1.5000 x 3000 |
| Day's Range | 0.6800 - 0.7040 |
| 52 Week Range | 0.4600 - 2.5500 |
| Volume | 233,295 |
| Avg. Volume | 403,608 |
| Market Cap | 110.557M |
| Beta (3Y Monthly) | 2.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1600 |
| Earnings Date | Oct 29, 2018 - Nov 2, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.02 |
- PR Newswire•5 days ago
DURECT Announces Patient Dosing in Phase 2a Proof-of-Concept Clinical Trial of Topical DUR-928 in Patients with Mild to Moderate Plaque Psoriasis
CUPERTINO, Calif., March 21, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) today announced it has commenced patient dosing in a Phase 2a proof-of-concept trial with topical DUR-928 in patients with mild to moderate plaque psoriasis. DUR-928, the lead investigational product in the Company's Epigenetic Regulator Program, is an endogenous, first-in-class small molecule, which may have broad applicability in chronic hepatic diseases such as nonalcoholic steatohepatitis (NASH), acute organ injuries such as alcoholic hepatitis (AH) and acute kidney injury (AKI), and in inflammatory skin disorders such as psoriasis and atopic dermatitis. "Commencing patient dosing in this proof-of-concept psoriasis trial is an important milestone in line with our focus for DUR-928 in 2019, which is to produce data with the potential to create significant commercial and partnering value," said James E. Brown, President and CEO of DURECT.
- Thomson Reuters StreetEvents•12 days ago
Edited Transcript of DRRX earnings conference call or presentation 7-Mar-19 9:30pm GMT
Q4 2018 DURECT Corp Earnings Call
- Zacks Small Cap Research•12 days ago
DRRX: DUR-928 Programs Accelerating. Anticipate NASH, Psoriasis Data Later This Year
By Brian Marckx, CFA NASDAQ:DRRX READ THE FULL DRRX RESEARCH REPORT Q4 Financial Results and Operational Update Last week Durect (NASDAQ:DRRX) reported financial results for their fourth quarter ending ...
- GuruFocus.com•17 days ago
Durect Corp (DRRX) Files 10-K for the Fiscal Year Ended on December 31, 2018
Durect Corp is a biopharmaceutical company. Warning! GuruFocus has detected 3 Warning Signs with DRRX. For the last quarter Durect Corp reported a revenue of $8.04 million, compared with the revenue of $20.75 million during the same period a year ago.
- PR Newswire•18 days ago
DURECT Corporation Announces Fourth Quarter and Full Year 2018 Financial Results and Update of Programs
Advancing To Next Dosing Cohort in Severe Alcoholic Hepatitis (AH) Patients Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , March 7, 2019 /PRNewswire/ -- DURECT Corporation ...
- PR Newswire•22 days ago
DURECT Corporation Invites You to Join its Fourth Quarter 2018 Earnings Conference Call
CUPERTINO, Calif. , March 4, 2019 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) fourth quarter 2018 financial results press release, you are invited to listen to a conference ...
- PR Newswire•27 days ago
DURECT Announces Plans to Submit to FDA a Full Response to the POSIMIR® Complete Response Letter
CUPERTINO, Calif., Feb. 27, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) today announced it has completed a comprehensive review of its POSIMIR® (bupivacaine extended-release solution) program and plans to submit a full response to the Complete Response Letter (CRL) it previously received from U.S. Food and Drug Administration (FDA). The submission will request FDA approval of POSIMIR based on what the Company and its advisors believe is adequate evidence of both safety and efficacy. DURECT commissioned the advisory services of Dr. Lee S. Simon to evaluate the adequacy of the existing POSIMIR package to address the issues raised in FDA correspondence, including the CRL.
- Simply Wall St.•28 days ago
DURECT Corporation (NASDAQ:DRRX): Time For A Financial Health Check
While small-cap stocks, such as DURECT Corporation (NASDAQ:DRRX) with its market cap of US$127m, are popular for their explosive growth, investors should also be aware of their balance sheet toRead More...
- GlobeNewswire•last month
Factors of Influence in 2019, Key Indicators and Opportunity within ARRIS International plc, Edwards Lifesciences, DENTSPLY SIRONA, Vail Resorts, Akers Biosciences, and DURECT — New Research Emphasizes Economic Growth
NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•last month
DURECT Corporation to Participate in the Berenberg NASH Day
CUPERTINO, Calif. , Feb. 21, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown , President and CEO, and Mike Arenberg , Chief Financial Officer, will be participating ...
- GlobeNewswire•2 months ago
Streetwise Reports Examines the Commercial Launch Planned for Schizophrenia Drug
DURECT Corp. (DRRX:NASDAQ), a biopharmaceutical company, noted that Indivior Plc announced that it will launch in the U.S. its drug for the treatment of schizophrenia, PERSERIS™, in February. Company mentioned: DURECT Corp. In September 2017, DURECT entered a patent purchase agreement whereby it assigned to Indivior UK Limited, an affiliate of Indivior PLC, certain patents that may provide further intellectual property protection for its drug PERSERIS.
- Zacks Small Cap Research•2 months ago
DRRX: Pipeline Update: Focus Is On Accelerating DUR-928 in NASH and Other High-Potential Indications
Earlier this week Durect (DRRX) provided a corporate and pipeline update. One of those areas is clearly NASH – an indication with significant unmet need and one that, if DRRX can build on the prior Phase 1b data, could represent meaningful upside to the share price in our opinion.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of DRRX earnings conference call or presentation 7-Nov-18 9:30pm GMT
Q3 2018 DURECT Corp Earnings Call
- PR Newswire•3 months ago
DURECT Corporation Provides Corporate Update
CUPERTINO, Calif., Jan. 7, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) has refined and focused its clinical development strategy for DUR-928, the lead product candidate in its Epigenetic Regulator Program, to prioritize indications with unmet medical needs where we expect to be able to generate near-term data with the potential to create significant commercial and partnering value. 1. Accelerate DUR-928 clinical trial in non-alcoholic steatohepatitis (NASH) patients. DURECT previously announced that it would be initiating a new clinical trial of orally-administered DUR-928 in NASH patients in the first half of 2019, and is now updating that guidance to indicate that the Company expects to begin enrolling patients in Q1 2019.
- Simply Wall St.•3 months ago
Here’s What We Think About DURECT Corporation’s (NASDAQ:DRRX) CEO Pay
James Brown became the CEO of DURECT Corporation (NASDAQ:DRRX) in 1998. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, we Read More...
- PR Newswire•3 months ago
DURECT Corporation Announces Investor Call to Provide Corporate Update
A live audio webcast of the presentation will be available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.
- PR Newswire•3 months ago
Commercial Launch Plans Announced for PERSERIS™ (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
CUPERTINO, Calif., Dec. 19, 2018 /PRNewswire/ -- DURECT Corporation (DRRX) today announced that Indivior PLC (INDV.L) stated on December 18, 2018 that it is moving ahead with the launch of PERSERIS™ in the U.S. with a sales force consisting of approximately 50 representatives. While PERSERIS™ has been available in the U.S. since November 19, 2018, Indivior stated that the commercial launch is scheduled to take place in February 2019. Indivior stated that its PERSERIS™ team is currently engaged in creating payor access, growing prescriber awareness and interest, as well as establishing its INSUPPORT™ patient hub. Indivior reiterated its confidence in its peak net revenue goal for PERSERIS™ of $200 to $300 million.
- PR Newswire•3 months ago
DURECT Corporation Announces Retirement of Dr. Felix Theeuwes as Chairman of the Board and Distinguished Scientist
David Hoffmann, Current Lead Independent Director and Chairman of the Audit Committee, to Assume Position of Chairman of the Board CUPERTINO, Calif. , Dec. 17, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: ...
- GlobeNewswire•4 months ago
Analysis: Positioning to Benefit within News Corporation, DURECT, Ecolab, MiX Telematics, Ship Finance International, and BCE — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•4 months ago
DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients
CUPERTINO, Calif. , Nov. 19, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it has amended its ongoing Phase 2a clinical trial of intravenously administered DUR-928 in patients ...
- Zacks Small Cap Research•4 months ago
DRRX: Protocol Amendment Speeds DUR-928 Ph2 AH Trial. PERSERIS FDA Approval Adds New Revenue Stream
DRRX is also eligible for single-digit percentage earn-outs based on U.S. sales of PERSERIS. Indivior indicated that they expect to have initial quantities available in Q4 ’18 and, based on the outcome of an appeal by Dr. Reddy’s lab (DRL) challenging the U.S. District Court of New Jersey’s preliminary injunction (PI) prohibiting DRL from importing or selling its generic buprenorphine/naloxone sublingual film product, expect to commence a full product launch. A favorable outcome (i.e.
- Simply Wall St.•4 months ago
Could DURECT Corporation’s (NASDAQ:DRRX) Investor Composition Influence The Stock Price?
The big shareholder groups in DURECT Corporation (NASDAQ:DRRX) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable Read More...
- Associated Press•5 months ago
Durect: 3Q Earnings Snapshot
On a per-share basis, the Cupertino, California-based company said it had a loss of 2 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- PR Newswire•5 months ago
DURECT Corporation Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , Nov. 7, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended ...
- PR Newswire•5 months ago
DURECT Corporation Invites You to Join its Third Quarter 2018 Earnings Conference Call
CUPERTINO, Calif. , Nov. 1, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (Nasdaq: DRRX) third quarter 2018 financial results press release, you are invited to listen to a conference call ...
